Brainomix Achieves Breakthrough in Stroke Imaging with FDA Clearance for New Feature

Brainomix Revolutionizes Stroke Care with FDA Approval



In a remarkable development for stroke treatment, Brainomix, a leading innovator in AI-powered imaging solutions, has recently secured FDA clearance for a patented feature in its Brainomix 360 platform. This novel capability allows healthcare professionals to determine ischemic core volumes using standard non-contrast CT (NCCT) images, making this technology more widely accessible and improving stroke patient outcomes.

Significance of the New Feature


The ability to accurately assess ischemic core volume is crucial for effectively triaging stroke patients. Traditionally, this assessment has relied on advanced imaging techniques such as CT Perfusion and MRI. However, with Brainomix 360's latest feature, doctors can now utilize routine NCCT scans, which are readily available in most healthcare settings. This advancement addresses a long-standing gap in stroke care, providing physicians across stroke networks with essential insights for informed treatment decisions and patient transfers, all based on familiar imaging methods.

Dr. Michalis Papadakis, CEO and Co-Founder of Brainomix, expressed enthusiasm regarding this innovation, stating, “This pivotal enhancement of our Brainomix 360 platform not only marks a significant leap in stroke imaging technology but also aligns with our mission to revolutionize stroke care through state-of-the-art solutions.” He further emphasized that this tool equips stroke teams to access high-precision information in real time, facilitating timely interventions such as thrombolysis and mechanical thrombectomy even within a 24-hour window after stroke onset.

Validated Effectiveness and Clinical Impact


The new NCCT core volume estimation feature has undergone rigorous validation in collaboration with several prominent stroke centers across the United States. Studies showcased that the performance of Brainomix's algorithm is on par with both CT Perfusion and MRI-derived assessments. This validation underlines the reliability of the tool and suggests a promising alternative to advanced imaging modalities for centers that may lack direct access to specialists in neuroimaging.

Dr. Mehdi Bouslama, a specialist in Neuroendovascular Surgery and Vascular Neurology at Broward Health in Florida, co-authored a study highlighting the algorithm’s effectiveness. He remarked, “The capability of Brainomix 360 to reliably estimate ischemic core volumes presents a viable and efficient option for medical centers that might not have immediate access to advanced imaging resources.”

In another complementary study published in the Journal of Neurointerventional Surgery by Dr. Kambiz Nael, it was found that the NCCT core volumes attained by Brainomix 360 were comparable to those derived from CT Perfusion scans. This highlights the potential of the Brainomix solution to enhance patient care by broadening the accessibility of advanced stroke treatment options for a larger patient population.

Future Prospects and Continued Innovation


Brainomix is dedicated to transforming stroke care with ongoing innovations in artificial intelligence and imaging technology. With a focus on expanding its platform, the company aims to improve the treatment rates and outcomes for patients who have suffered strokes. According to the extensive real-world evaluation of their system involving over 450,000 patients, the Brainomix 360 platform has led to an impressive increase in mechanical thrombectomy rates by more than 50%, indicating a strong impact on patient care and treatment efficacy.

As Brainomix continues to expand its reach, it is essential for interested medical professionals to stay informed about new developments. An upcoming webinar titled "Imaging the Core on NCCT: Unlocking Stroke Insights Across Networks" is scheduled for April 24th at 12 PM EST, providing further insights into this revolutionary advancement in stroke imaging. Registration for the webinar is available through their official site.

Company Background and Mission


Founded as a spinout from the University of Oxford, Brainomix specializes in developing AI-driven tools aimed at enhancing precision medicine in stroke and lung fibrosis treatments. The company has grown into a commercial powerhouse with operations spanning across more than 20 countries. Backed by top healthtech investors, Brainomix is committed to delivering clinically validated, award-winning imaging biomarkers and software solutions adopted by numerous global hospitals.

For additional information about Brainomix and their trailblazing technology, visit www.brainomix.com and follow them on social media platforms such as Twitter, LinkedIn, and Facebook.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.